SEC Comment Letter 0000000000-22-012620 to TALPHERA, INC. (TLPH)
TALPHERA, INC.
Date: Nov. 21, 2022 · CIK: 0001427925 · Accession: 0000000000-22-012620
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268396
Letter
United States securities and exchange commission logo November 21, 2022 Vincent J. Angotti Chief Executive Officer AcelRx Pharmaceuticals Inc. 25821 Industrial Boulevard, Suite 400 Hayward, CA 94545 Re:AcelRx Pharmaceuticals Inc. Registration Statement on Form S-3 Filed November 15, 2022 File No. 333-268396 Dear Vincent J. Angotti: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
November 21, 2022
Vincent J. Angotti
Chief Executive Officer
AcelRx Pharmaceuticals Inc.
25821 Industrial Boulevard, Suite 400
Hayward, CA 94545
Re:AcelRx Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed November 15, 2022
File No. 333-268396
Dear Vincent J. Angotti:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences